1 / 20

Vaxil BioTherapeutics Ltd.

2. Overview. . Vaxil has developed VaxHit, a technology to identify Vaccine Candidate (VCs) with the ability to induce specific, robust and broader T-cell immunity for different cancers and key infectious diseases. Lead product ImMucin, a MUC1 cancer vaccine is being evaluated in a Phase I/II cl

roddy
Download Presentation

Vaxil BioTherapeutics Ltd.

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

    1. 1 Vaxil BioTherapeutics Ltd.

    5. Vaccines for Adoptive immunity: Rational & Challenges

    9. Vaxil’s technological approach: VaxHit (I)

    11. Therapeutic vaccines: The essentials

    12. 12 Vaxil’s approach: Comparison vs. current solutions

    14. ImMucin: Potential for “Pipeline In A Product”

    15. ImMucin: Potential for “Pipeline In A Product”

    16. ImMucin (VXL100): Anti-MUC1 vaccine

    17. ImMucin: in-vitro & ex-vivo Characterization

    19. ImMucin: A first in man study

    20. Thank you

More Related